NCT07347574Recruiting
NeuroCare Community Project: A Community Based Prospective Observational Study for Early Alzheimer's Detection in HK
NeuroCare Community Project: A Community Based Prospective Observational Study for Early Alzheimer's Detection in Hong Kong
Source: ClinicalTrials.gov · Last updated 8 Jul 2026
Brief summary (registry, in English)
Population aging is reshaping societal dynamics and presents significant global challenges. By 2050, it is projected that 1.6 billion people worldwide will be over the age of 65. Given that aging is the primary risk factor for many common chronic diseases, reducing the burden of age-related illnesses and promoting healthy aging have become critical public health priorities. Notably, Hong Kong has one of the largest proportions of elderly and the highest life expectancy in the world. Dementia, particularly Alzheimer's disease (AD), is a multifaceted condition influenced by both biological and behavioral factors. There is a paucity of robust, community-based prospective data in ethnic Chinese populations that integrate clinical and cognitive measures with objective biomarkers and neuroimaging, especially at earlier stages such as mild cognitive impairment (MCI) and early AD. This community-based project aims to establish a cohort of elderly in Hong Kong, with longitudinal follow-up for 2-3 years. A key strength of this research is the incorporation of a panel of blood biomarkers, which will provide a less invasive and more affordable screening tool to identify Alzheimer's disease at a much earlier stage in the community. Additionally, through benchmark with MRI and PET imaging gold standard, these biomarkers have the potential to predict the conversion risk 1) from clinically normal to mild cognitive impairment and Alzheimer's disease (AD dementia); 2) from clinically MCI to Alzheimer's disease (MCI-AD dementia) or remain static; and differentiate non-AD dementia from Alzheimer's disease (dementia-AD). Collectively, these data will facilitate monitoring of aging processes and cognitive decline, help to identify candidate modifiable factors associated with resilience, and generate a de-identified, Chinese-specific resource to advance healthy aging in Hong Kong.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2500 (estimated)
- First submitted
- 9 Jan 2026
- Start date
- 23 Mar 2026
- Primary completion date
- 30 Dec 2030
- Lead sponsor
- Hong Kong University of Science and Technology
- Diseases
- Alzheimer disease
- NCT number
- NCT07347574
What you commit to
- Study type: Observational
- Planned participants: 2500
- From 23 Mar 2026 to the primary completion date, 30 Dec 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known illness that prevents longitudinal follow up or uncontrolled medical illness such as neurodevelopmental disorder, neurodegenerative disease, epilepsy, central nervous system infection, neuroinflammatory diseases, brain tumor, cerebrovascular diseases, history of major psychiatric illness, history of major head injury with altered consciousness, sexually transmitted disease including HIV and syphilis, visual and auditory disability, history of alcohol dependence, substance use disorder, systemic autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, or malignancy.
- Active delirium or evidence of reversible/secondary causes of cognitive impairment (e.g., vitamin B12 deficiency, hypothyroidism) until treated/ stabilized
Other
- Lacks capacity to consent even with an informant present
- Refuses or is unable to provide blood samples or complete essential assessments
- Currently enrolled in another clinical trial that could interfere with this study
Who the study is looking for
- Mentally capable of providing informed consent, with or without an informant present
- Willing and able to undergo blood draw and complete study related assessments; willing to be contacted for follow-up
Age in the registry: 60 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hong Kong University of Science and Technology Coordinator of this site? Confirm its status | Hong Kong | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.